Abstract

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor in southern China. Cucurbitacin B (CuB) is a tetracyclic triterpene compound isolated from Cucurbitaceae plants which has anti-inflammation and antitumor properties and low toxic side effects. In this study, we use a series of wet experiments and network pharmacology analyses to explore the effects of CuB on cell proliferation, migration, invasion, and apoptosis of highly metastatic 5-8F NPC cells. The findings suggest that CuB inhibits NPC cells in a time- and dose-dependent manner and that cancer migration and invasion abilities decrease significantly after CuB treatments. Mechanistically, CuB could increase the proportion of cells in the G2/M phase and reduce it in the G0/G1 phase, leading to apoptosis. The network pharmacological analyses and wet experiments uncovered that the MAPK pathway is a central target by pathway enrichment analysis, affecting the fate of cancer cells and influencing proliferation and apoptosis. Taken together, our study reveals that CuB could effectively inhibit 5-8F NPC cell proliferation, migration, and invasion via cell cycle blockage and cell apoptosis. Collectively, we have shown that CuB is a promising anti-NPC candidate compound for future preclinical study.

Highlights

  • Nasopharyngeal carcinoma (NPC) is the most common malignant tumor of the nasopharynx

  • We examined the effect of Cucurbitacin B (CuB) on the highly metastatic NPC 5-8F cells and reveal its possible mechanism of action using in vitro wet experiments and bioinformatics analyses

  • Our findings suggest that CuB could effectively inhibit 5-8F cell proliferation, migration, and invasion via cell cycle blockage and apoptosis

Read more

Summary

Introduction

Nasopharyngeal carcinoma (NPC) is the most common malignant tumor of the nasopharynx. More than 45% of the new cases were in China, several times higher than the global average incidence rate, and in some provinces, the rate exceeded 30/100,000 [1, 2]. High survival rates are seen in patients with stage II cancer who underwent radiotherapy alone, but 10-15% of patients develop recurrence and distant metastasis [9]. Combined chemotherapy can improve patient survival rate and Journal of Nanomaterials reduce the rate of recurrence and metastasis, but the toxicity and side effects of chemotherapy drugs seem to do more harm than good [10, 11]. There is an urgent need to seek safe and effective radiotherapy adjuvant drugs with low toxicity and side effects which will help to reduce the recurrence and distant metastasis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call